"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

To meet that, ASML’s order intake needs to pick up significantly, so there are some short-term headwinds." Shares in MP ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

"Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a statistically significant and clinically meaningful reduction in mean-seated ...